Clinical Briefs in Primary Care – March 1, 2018
March 1, 2018
View Issues
-
Long-term Outcomes for Obesity
The evidence of the advantages of bariatric surgery over medical management continues to accrue.
-
Biomarkers for Tight Control of Crohn’s Disease
The authors suggested that treatment escalation based on the combination of clinical symptoms with biomarkers produces more favorable outcomes.
-
Postprandial Glucose Excursions in Type 2 Diabetes
The most recent American Diabetes Association 2018 guidelines suggest that for persons with established cardiovascular disease who have not attained glucose goals, incorporation of agents that have shown cardiovascular risk reduction (i.e., canagliflozin, empagliflozin, liraglutide) should be a priority.
-
Cardiovascular Benefits of Pharmacotherapies for Type 2 Diabetes
The most recent American Diabetes Association 2018 guidance for pharmacotherapy of type 2 diabetes mellitus suggests that for patients with existing cardiovascular (CV) disease who are uncontrolled on metformin and lifestyle, consideration should be given to prioritizing agents demonstrated to provide CV risk reduction (empagliflozin, liraglutide, and canagliflozin).
-
Osteoblast Modulation in Osteoporosis Treatment
Most pharmacologic interventions currently in use for treatment or prevention of osteoporosis rely on osteoclast inhibition to enhance (or at least maintain) bone mineral density. In contrast, teriparatide primarily works by stimulation of osteoblasts.
-
The Vagaries of Reported Penicillin Allergy
The literature says that > 90% of patients who report a history of penicillin allergy can tolerate penicillin. Unstimulated penicillin sensitivity wanes over time: By age 10 years, 80% of allergic subjects are no longer allergic.